CELLINK AB is set to acquire Ginolis Oy for 70 million euros, enhancing its capabilities in medical automation solutions.

Target Information

CELLINK AB (publ) has successfully negotiated an agreement to acquire all shares of Ginolis Oy, a leading provider of innovative robot-based automation solutions. This acquisition represents a significant strategic move into the healthcare sector, with Ginolis Oy known for creating automation solutions that cater to the manufacturing of various medical disposables and point-of-care tests, including widely-used Covid-19 testing kits. The transaction is structured on a cash- and debt-free basis, valuing Ginolis Oy at 70 million euros.

Industry Overview

The automation and robotics industry, particularly within the healthcare sector, has experienced rapid growth, driven by the increasing demand for efficient manufacturing processes and the need for quick diagnostic testing. Countries like Finland, where Ginolis Oy is based, have established themselves as leaders in technological advancements, making significant strides in automation to enhance productivity and precision in medical manufacturing.

In Finland, the healthcare industry is well-supported by favorable regulations, substantial investment in research and development, and a strong focus on innovati